
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39289410
72105
10.1038/s41598-024-72105-8
Article
Impairment of health-related quality of life among people with type 2 diabetes and advanced liver fibrosis
Michel Maurice 12
Funuyet-Salas Jesús 23
Doll Michelle 2
Alqahtani Saleh A. 45
Armandi Angelo 26
Labenz Christian 2
Galle Peter R. 2
Schattenberg Jörn M. joern.schattenberg@uks.eu

127
1 Department of Internal Medicine II, University Medical Centre Saarland, Homburg, Germany
2 grid.410607.4 Department of Internal Medicine I, University Medical Centre Mainz, Mainz, Germany
3 https://ror.org/0075gfd51 grid.449008.1 0000 0004 1795 4150 Loyola University Andalusia, Sevilla, Spain
4 https://ror.org/05n0wgt02 grid.415310.2 0000 0001 2191 4301 Liver Transplantation Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
5 https://ror.org/00za53h95 grid.21107.35 0000 0001 2171 9311 Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD USA
6 https://ror.org/048tbm396 grid.7605.4 0000 0001 2336 6580 Department of Medical Sciences, University of Turin, Turin, Italy
7 https://ror.org/01jdpyv68 grid.11749.3a 0000 0001 2167 7588 Saarland University, Saarbrücken, Germany
17 9 2024
17 9 2024
2024
14 2165020 7 2024
3 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
People with type 2 diabetes mellitus (T2DM) show a high prevalence of steatotic liver disease (SLD), and especially metabolic dysfunction-associated steatotic liver disease (MASLD), with liver fibrosis. Their health-related quality of life (HRQL) is affected by multiple in part overlapping factors and aggravated by metabolic and liver-related comorbidities, including liver fibrosis stage. The aim of this study was to investigate the effect size of advanced fibrosis (AF) on the HRQL in people with T2DM. A total of 149 individuals with T2DM treated at a primary care provider within the German disease management program (DMP) were included in the final analysis. Vibration-controlled transient elastography (VCTE) was used to non-invasively detect steatosis and AF. The EQ-5D-3L questionnaire was used to assess the HRQL. Uni- and multivariable linear regression models were used to identify independent predictors of impaired HRQL. The majority was male (63.1%), and the median age was 67 years (IQR 59; 71). In the entire cohort, the prevalence of MASLD and AF was 70.7% and 19.5%, respectively. People with T2DM and AF had an overall lower HRQL in comparison to those without AF (p < 0.001). Obesity (β: − 0.247; 95% CI − 0.419, − 0.077) and AF (β: − 0.222; 95% CI − 0.383, − 0.051) remained independent predictors of a poor HRQL. In turn, T2DM-related comorbidities were not predictive of an impaired HRQL. Obesity and AF negatively affect the HRQL in patients with SLD and T2DM in primary care. Awareness of liver health and specific interventions may improve patient-reported and liver-related outcomes in people with T2DM.

Keywords

MASLD
Advanced fibrosis
T2DM
Obesity
HRQL
Subject terms

Hepatology
Type 2 diabetes
Obesity
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes (8981)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Steatotic liver disease (SLD) and especially metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease with an estimated global prevalence of 30%1. Major risk factors for developing MASLD are type 2 diabetes mellitus (T2DM) and obesity, with a markedly elevated prevalence of MASLD if these conditions are present2–4. Along the disease course, MASLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), with increasing scarring of liver tissue resulting in liver fibrosis5. Progression of liver fibrosis can lead to advanced fibrosis (AF; F3) and even liver cirrhosis (F4), with increased morbidity and mortality6. As a result of the increasing burden of chronic liver disease related to MASLD, non-invasive tests (NITs), including vibration-controlled transient elastography (VCTE, Fibroscan®), have been developed to identify patients at risk in need of more intensive care and surveillance7. However, only few data on the use of VCTE is available from primary care settings, although the majority of patients with T2DM are routinely seen by primary care providers8.

An important aspect in the care of patients is the health-related quality of life (HRQL)—a term that describes the patient’s physical, mental, and social functioning, individual perception of their health status, and the overall well-being associated with the disease. Several questionnaires have been developed for the assessment of the HRQL. A generic questionnaire is the EQ-5D-3L that can assess the current health state, and provide an estimate of the overall HRQL9. The EQ-5D-3L consists of five dimensions that capture various aspects of someone’s health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), with three levels of response (no problems, moderate problems, or extreme problems) each. It is a validated tool for the assessment of the HRQL that has also been used in the context of T2DM or SLD/MASLD10,11. Analyzing the HRQL has major implications for treatment adherence and success, especially within the context of chronic conditions requiring long-term care such as T2DM and MASLD12. Patients with MASLD and higher disease stages, including MASH and fibrosis, report a lower HRQL10,13. In patients with T2DM, impairment of HRQL is often associated with T2DM-related comorbidities, including microvascular and macrovascular complications14–16. However, despite the high prevalence of SLD and AF in people with T2DM, the independent effect size of the liver phenotype on the HRQL remains to be established. Therefore, the aim of this prospective study was to investigate the effect size of AF on the HRQL in people with T2DM.

Methods

Study design and population

A total of 153 participants with a diagnosis of T2DM were enrolled at a primary care provider (Diabetology Practice Mainz) with a focus on T2DM in Mainz, Germany, between 2019 and 2021 (Supplementary Fig. 1). These individuals were recruited during their routine visits within the T2DM disease management program (DMP). The DMP is a specifically designed program for the routine assessment of T2DM-related comorbidities, including microvascular and macrovascular complications, to decrease their associated mortality17. All participants had to be at least 18 years of age and provide written informed consent before study inclusion. Only participants with a diagnosis of T2DM were eligible for study inclusion with no specific differences in disease severity, treatment, or the number of related comorbidities. Due to missing data or invalid VCTE measurements, four individuals were excluded from the final analysis (n = 149). Anthropometric data, patient history, and laboratory values were obtained from each participant at study inclusion. Body mass index (BMI) was calculated using height and weight (BMI = weight [kg]/height2 [m2]). Waist circumference (cm) was assessed at study inclusion. Metabolic syndrome (MetS) was defined according to the international diabetes federation18. The alcohol use disorders identification test (AUDIT) was used to screen for alcohol consumption, and a score ≥ 8 was considered at least harmful alcohol consumption19.

Non-invasive assessment of hepatic steatosis (HS) and advanced fibrosis (AF)

Hepatic steatosis (HS) for a diagnosis of SLD and advanced fibrosis (AF) were non-invasively assessed using vibration-controlled transient elastography (VCTE; Fibroscan® 430 mini) and defined as a controlled attenuation parameter (CAP) of  ≥ 275 and a liver stiffness measurement (LSM) of ≥ 12, respectively. CAP was assessed by a standard exam of 10 measurements. The cutoffs were chosen based on recent EASL guidelines on the use of NITs and current guidelines on the care of MASLD20,21. Either the M or XL probe was used as recommended by the device for each participant. MASLD was defined according to current practice guidelines after the exclusion of high alcohol consumption (based on AUDIT) or other secondary causes of SLD21.

Assessment of health-related quality of life (HRQL)

The validated German version of the EQ-5D-3L questionnaire was used for the assessment of the HRQL. The EQ-5D is a generic measure to quantify an individual’s HRQL, which has also been used in people with T2DM and patients with chronic liver disease, including MASH with advanced fibrosis10,11,22. The questionnaire contains five dimensions, mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, that each captures various aspects of the HRQL. Each dimension has three response levels ranging from no problems, moderate problems to extreme problems. The EQ VAS indicates the overall current health, ranging from 0 (the worst health) to 100 (the best health). In turn, the time trade-off (TTO) index value represents an overall score of the five dimensions based on a country-specific value set that reflects the respective health state of that country. For this study, the German value set was used23. Higher scores on the five dimensions indicate a lower HRQL, whereas higher scores on the VAS and TTO indicate a better HRQL.

Ethics

All patients provided written informed consent. The study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki (sixth revision, 2008). The study protocol was approved by the ethics committee of the Landesärztekammer Rhineland–Palatinate [Nr. 873.199.10 (7208)].

Statistics

Descriptive variables are presented as median values with interquartile ranges (IQR 25th; 75th) or mean values with SD. Categorical variables are shown as frequencies with percentages. For the comparison of differences between groups of categorical variables, the Mann–Whitney U test was used. The chi-squared test was applied for the comparison of two or more patient groups. All tests were two-tailed, and statistically significant values were defined as p < 0.05. Linear regression models were built to identify independent predictors of an impaired HRQL (TTO, VAS). All variables with a p-value of < 0.05 in the univariable analysis, and adjusted for age and sex, were then analyzed in a multivariable linear regression model. Cohen’s d (for continuous variables) and w (for categorical variables) were computed as effect size indexes. Effect sizes are defined as null (d < 0.2; w < 0.1), small (d ≥ 0.2; w ≥ 0.1), medium (d ≥ 0.5; w ≥ 0.3), or large (d ≥ 0.8; w ≥ 0.5)24. For all data analyses and statistical tests, IBM SPSS Statistic Version 23.0 (IBM Corp.) was used. Microsoft Excel 2016 (Microsoft Corp.) or Microsoft PowerPoint 2016 (Microsoft Corp.) were used for all figures.

Results

Demographic and clinical characteristics

The median age in this cohort was 67 (IQR 59; 71) years and 36.9% were females. Advanced fibrosis (AF) was evident in 19.5% (n = 29). The prevalence of SLD was 77.9% (n = 116), of whom the majority had MASLD (n = 104, 70.7%). Cardiovascular disease (CVD) was more prevalent in people with AF (p = 0.002, d = 0.256). The median CAP was 336 dB/m (IQR 280.5; 371.0) in the entire cohort, with a significantly higher median CAP in those with AF compared to no AF (p = 0.043, d = −0.481). Metabolic risk factors were more common in the subgroup with AF. Higher median GGT lab values were detected in those with AF (p < 0.001, d = −0.518). More individuals were on insulin as part of their T2DM-related treatment in those with AF compared to no AF (p = 0.008, d = 0.217). No major differences were seen between males and females, although a higher alcohol consumption was more evident in males (p = 0.031, d = −0.177; Supplementary Table 1). Baseline characteristics and a comparison between people with T2DM presenting with and without AF are summarized in Table 1. Table 1 Demographics, clinical characteristics, and comparison between AF and no AF.

Variable	Total cohort (n = 149)	No AF (n = 120, 80.5%)	AF (n = 29, 19.5%)	p-value	Effect sizes	
n (% or IQR)	n (% or IQR)	n (% or IQR)	Cohen’s d or w	
General characteristics	
 Age in years	67.0 (59.0; 71.0)	67.0 (59.0; 71.0)	64.0 (58.5; 69.0)	0.150	0.345 S	
 Time since diagnosis	11.0 (6.0; 18.5)	11.0 (5.3; 17.0)	12.0 (7.0; 21.5)	0.330	− 0.176 N	
 Sex, female	55 (36.9)	42 (35)	13 (44.8)	0.325	0.081 N	
 History of cancer	13 (8.7)	10 (8.3)	3 (10.3)	0.730	0.028 N	
 Harmful alcohol consumption (AUDIT ≥ 8) n = 148	12 (8.1)	8 (6.7)	4 (14.3)	0.184	0.109 S	
VCTE	
 CAP (dB/m)	336 (280.5; 371.0)	327.5 (274.0; 368.8)	361.0 (301.5; 387.5)	0.043	 − 0.481 S	
 SLD (CAP ≥ 275 dB/m)	116 (77.9)	89 (74.2)	27 (93.1)	0.028	0.181 S	
 MASLD n = 147	104 (70.7)	81 (67.5)	23 (85.2)	0.068	0.151 S	
 LSM (kPa)	7.2 (5.6; 10.9)	6.4 (5.3; 8.4)	18 (14.2; 20.5)	 < 0.001	 − 1.358 L	
Metabolic comorbidities	
 BMI (kg/m2)	31.8 (27.6; 35.5)	30.3 (27.1; 34.3)	35.3 (33.5; 42.2)	 < 0.001	 − 1.057 L	
 Obesity (> 30 kg/m2)	89 (59.7)	62 (51.7)	27 (93.1)	0.001	0.335 M	
 Waist circumference (cm)	110 (100.0; 123.5)	106.5 (99.0; 120.8)	124.0 (114.5; 138.0)	 < 0.001	 − 1.189 L	
 Hyperlipidemia	93 (62.4)	75 (62.5)	18 (62.1)	0.966	0.056 N	
 Arterial hypertension	134 (89.9)	106 (88.3)	28 (96.6)	0.187	0.108 S	
 MetS	89 (59.7)	62 (51.7)	27 (93.1)	 < 0.001	0.335 M	
Laboratory values	
 GGT (U/l) n = 148	37.5 (26.3; 56.8)	34.0 (26.0; 48.0)	60.0 (37.0; 83.5)	 < 0.001	 − 0.518 M	
 TG Triglycerides (mg/dl) n = 147	165 (112; 249)	162.5 (105.0; 245.3)	184.0 (119.5; 299.5)	0.158	 − 0.182 N	
 TC (mg/dl) n = 148	190.0 (156.0; 219.8)	190.0 (155.0; 222.0)	189.0 (157.5; 213.5)	0.519	0.198 N	
 Platelets (/nl) n = 148	221.0 (193.0; 226.3)	221.0 (193.0; 273.0)	218.0 (186.0; 247.0)	0.614	0.043 N	
 HbA1c (%) n = 148	7.0 (6.5; 7.7)	6.9 (6.4; 7.6)	7.5 (6.7; 8.4)	0.031	− 0.418 S	
T2DM-related comorbidities	
 CVD	55 (36.9)	37 (30.8)	18 (62.1)	0.002	0.256 S	
 CKD	49 (32.9)	41 (34.2)	8 (27.6)	0.498	 − 0.055 N	
 Polyneuropathy	47 (31.5)	35 (29.2)	12 (41.4)	0.204	0.104 S	
 Retinopathy	14 (9.4)	7 (5.8)	7 (24.1)	0.002	0.248 S	
 DFS	19 (12.8)	13 (10.8)	6 (20.7)	0.153	0.117 S	
T2DM-related medication	
 Metformin	92 (61.7)	74 (61.7)	18 (62.1)	0.968	0.003 N	
 Insulin	75 (50.3)	54 (45.0)	21 (72.4)	0.008	0.217 S	
 SGLT2 inhibitor	22 (14.8)	15 (12.5)	7 (24.1)	0.113	0.130 S	
 No treatment	16 (10.7)	15 (12.5)	1 (3.4)	0.158	 − 0.116 S	
AF advanced fibrosis, AUDIT alcohol use disorders identification test, VCTE vibration-controlled transient elastography, CAP controlled attenuation parameter, MASLD metabolic dysfunction-associated steatotic liver disease, LSM liver stiffness measurement, BMI body mass index, MetS metabolic syndrome, GGT gamma-glutamyl transferase, SLD steatotic liver disease, TG triglycerides, TC total cholesterol, CVD cardiovascular disease, CKD chronic kidney disease, DFS diabetic foot syndrome.

Effect sizes: N, null; S, small; M, medium; L, large. Data are expressed as numbers, median, percentage (%), or interquartile ranges (IQR 25th; 75th).

P-values refer to the comparison between no AF vs. AF. Boldface indicates statistical significance. A p-value < 0.05 was considered statistically significant.

HRQL in people with T2DM

The mean EQ-5D-3L VAS and TTO index value was 71.9 ± 18.4 and 0.85 ± 0.21, respectively. The highest mean scores were seen in the pain/discomfort (1.70 ± 0.61) and mobility (1.28 ± 0.47) dimensions, whereas the lowest mean score was detected in the self-care (1.05 ± 0.21) dimension (Table 2). A high proportion of people with T2DM reported moderate and extreme problems in the pain/discomfort dimension in comparison to the other dimensions (Fig. 1). The anxiety/depression dimension was the only dimension to show a significant difference between males and females (1.20 ± 0.49 vs. 1.34 ± 0.55, p = 0.043, d = −0.269) (Supplementary Table 2). Table 2 Mean scores of the EQ-5D-3L questionnaire.

Variable	Total cohort	No AF	AF	p-value	Effect sizes
Cohen’s d	
EQ-5D-3L	
 Mobility n = 148	1.28 ± 0.47	1.22 ± 0.41	1.55 ± 0.57	0.001	 − 0.665 M	
 Self-care	1.05 ± 0.21	1.03 ± 0.18	1.10 ± 0.31	0.110	 − 0.276 S	
 Usual activities	1.20 ± 0.40	1.17 ± 0.37	1.34 ± 0.48	0.032	 − 0.397 S	
 Pain/discomfort n = 147	1.70 ± 0.61	1.64 ± 0.59	1.93 ± 0.65	0.027	 − 0.467 S	
 Anxiety/depression	1.26 ± 0.52	1.21 ± 0.45	1.45 ± 0.74	0.102	 − 0.392 S	
 VAS n = 143	71.9 ± 18.4	74.8 ± 16.4	59.9 ± 21.3	 < 0.001	0.784 M	
 TTO index-value n = 146	0.85 ± 0.21	0.88 ± 0.17	0.71 ± 0.29	0.001	0.715 M	
Data are expressed as means with standard deviation (± SD). Data are expressed as means with standard deviation. Boldface indicates statistical significance. Effect sizes: S, small; M, medium.

A p-value < 0.05 was considered statistically significant.

Fig. 1 Distribution of the EQ-5D-3L dimensions in people with T2DM presenting with advanced fibrosis (AF) or without advanced fibrosis (no AF). The EQ-5D-3L consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of these dimensions is divided into three levels of perceived problems: no problems, moderate problems, or extreme problems.

Comparison of the HRQL between AF and without AF

The HRQL was overall lower in AF (VAS: no AF 74.8 ± 16.4 vs. AF 59.9 ± 21.3, p < 0.001, d = 0.784; TTO: no AF 0.88 ± 0.17 vs. AF 0.71 ± 0.29, p = 0.001, d = 0.715). Significantly higher mean scores for mobility (1.55 ± 0.57, p = 0.001, d = −0.665), usual activities (1.34 ± 0.48, p = 0.032, d = −0.397), and pain/discomfort (1.93 ± 0.65, p = 0.027, d = −0.467) dimensions were seen in those with AF (Table 2). Although the mean score of the anxiety/depression dimension was higher in AF, no significant difference was seen in the comparison to those without AF. In the pain/discomfort and mobility dimensions, more individuals with AF reported moderate and extreme problems compared to no AF. Furthermore, those with AF showed the second-highest distribution of extreme problems in the anxiety/depression dimension (Fig. 2). In addition, a comparison between people with T2DM presenting with SLD and without SLD and/or obesity is shown in Supplementary Table 3 and Supplementary Table 4, respectively.Fig. 2 Distribution of the EQ-5D-3L dimensions in people with T2DM in the entire cohort. The EQ-5D-3L consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of these dimensions is divided into three levels of perceived problems: no problems, moderate problems, or extreme problems.

Clinical predictors of impaired HRQL in people with T2DM

Two linear regression models, based on the TTO index value and the VAS, were built to identify independent predictors of impaired HRQL in people with T2DM (Table 3, Table 4). The variables time since diagnosis, metabolic risk factors (obesity, waist circumference, MetS), liver-related comorbidities (SLD, AF), T2DM-related comorbidities (CVD, retinopathy, polyneuropathy, and DFS), and treatment with insulin were all associated with a lower HRQL in the univariable analysis. In the multivariable linear regression analysis, obesity (β: −0.225; 95% CI −0.399, −0.050) and AF (β: −0.171; 95% CI −0.322, −0.001) remained the only independent predictors of a poor HRQL (Table 3). Table 3 Clinical predictors of impaired HRQL in T2DM according to TTO index value.

Variables	Univariable analysis	Multivariable analysis†	
β	95% CI	p-value	β	95% CI	p-value	
General characteristics	
 Age	 − 0.150	 − 0.339, 0.013	0.070	 − 0.144	 − 0.346, 0.035	0.108	
 Time since diagnosis	 − 0.236	 − 0.386, − 0.074	0.004	 − 0.069	 − 0.250, 0.117	0.472	
 Sex, female	 − 0.072	 − 0.237, 0.093	0.390	 − 0.129	 − 0.285, 0.026	0.102	
 History of cancer	0.064	 − 0.093, 0.211	0.443				
 Harmful alcohol consumption	0.013	 − 0.151, 0.177	0.874				
Metabolic comorbidities	
 Obesity	 − 0.298	 − 0.455, − 0.141	 < 0.001	 − 0.225	 − 0.399, − 0.050	0.012	
 Waist circumference	 − 0.329	 − 0.481, − 0.172	 < 0.001				
 Arterial hypertension	 − 0.033	 − 0.211, 0.142	0.696				
 Hyperlipidemia	0.104	 − 0.059, 0.267	0.211				
 Metabolic syndrome	 − 0.298	 − 0.455, − 0.140	 < 0.001				
VCTE	
 SLD	 − 0.175	 − 0.343, − 0.013	0.035	 − 0.036	 − 0.204, 0.131	0.667	
 AF	 − 0.318	 − 0.460, − 0.157	 < 0.001	 − 0.171	 − 0.332, − 0.001	0.049	
Laboratory values	
 HbA1c	 − 0.061	 − 0.256, 0.118	0.466				
 GGT	 − 0.024	 − 0.223, 0.166	0.773				
T2DM-related comorbidities	
 CVD	 − 0.248	 − 0.393, − 0.085	0.003	 − 0.104	 − 0.265, 0.064	0.228	
 CKD	 − 0.073	 − 0.236, 0.090	0.379				
 Retinopathy	 − 0.194	 − 0.339, − 0.031	0.019	 − 0.068	 − 0.221, 0.091	0.411	
 Polyneuropathy	 − 0.250	 − 0.406, − 0.090	0.002	 − 0.094	 − 0.275, 0.089	0.315	
 DFS	 − 0.197	 − 0.322, − 0.033	0.017	 − 0.046	 − 0.199, 0.114	0.592	
T2DM-related medication	
 Metformin	0.055	 − 0.108, 0.218	0.507				
 Insulin	 − 0.228	 − 0.387, − 0.068	0.006	 − 0.028	 − 0.206, 0.151	0.761	
 SGLT2 Inhibitor	 − 0.053	 − 0.206, 0.106	0.525				
 No treatment	0.105	 − 0.054, 0.249	0.205				
Univariable and multivariable linear regression analysis is shown. With all factors showing a p-value < 0.05 and adjusted for age and sex, a multivariable linear regression model was built. The variables waist circumference and MetS were excluded from the multivariable analysis to avoid multicollinearity. Confidence interval (CI) and beta (β) show each standardized values. Boldface indicates statistical significance.

A p-value < 0.05 was considered statistically significant.

†Multivariable linear regression analysis (n = 146): age, sex, time since diagnosis, obesity, SLD, AF, CVD, retinopathy, polyneuropathy, DFS, insulin.

Table 4 Clinical predictors of impaired HRQL in T2DM according to VAS.

Variables	VAS	
Univariable analysis	Multivariable analysis†	
β	95% CI	p-value	β	95% CI	p-value	
General characteristics	
 Age	 − 0.140	 − 0.331, 0.027	0.095	 − 0.171	 − 0.369, − 0.003	0.046	
 Time since diagnosis	 − 0.106	 − 0.265, 0.058	0.208				
 Sex, female	0.093	 − 0.073, 0.262	0.267	0.052	 − 0.106, 0.210	0.514	
 History of cancer	0.033	 − 0.122, 0.182	0.696				
 Harmful alcohol consumption	 − 0.061	 − 0.224, 0.104	0.469				
Metabolic comorbidities	
 Obesity	 − 0.292	 − 0.454, − 0.134	 < 0.001	 − 0.247	 − 0.419, − 0.077	0.005	
 Waist circumference	 − 0.361	 − 0.528, − 0.210	 < 0.001				
 Arterial hypertension	 − 0.155	 − 0.339, 0.010	0.065				
 Hyperlipidemia	0.097	 − 0.069, 0.262	0.251				
 MetS	 − 0.292	 − 0.453, − 0.133	 < 0.001				
VCTE	
 SLD	 − 0.078	 − 0.252, 0.091	0.354				
 AF	 − 0.322	 − 0.468, − 0.160	 < 0.001	 − 0.222	 − 0.383, − 0.051	0.011	
Laboratory values	
 HbA1c	 − 0.079	 − 0.286, 0.102	0.351				
 GGT	 − 0.057	 − 0.262, 0.129	0.501				
T2DM-related comorbidities	
 CVD	 − 0.247	 − 0.393, − 0.082	0.003	 − 0.139	 − 0.298, 0.031	0.110	
 CKD	 − 0.056	 − 0.217, 0.108	0.509				
 Retinopathy	 − 0.116	 − 0.265, 0.047	0.168				
 Polyneuropathy	 − 0.202	 − 0.358, − 0.038	0.015	 − 0.031	 − 0.212, 0.151	0.740	
 DFS	 − 0.175	 − 0.311, − 0.010	0.037	 − 0.043	 − 0.195, 0.116	0.616	
T2DM-related medication	
 Metformin	 − 0.063	 − 0.228, 0.102	0.452				
 Insulin	 − 0.175	 − 0.337, − 0.011	0.037	 − 0.005	 − 0.170, 0.161	0.954	
 SGLT2 Inhibitor	 − 0.067	 − 0.219, 0.093	0.426				
 No treatment	0.107	 − 0.055, 0.257	0.202				
Univariable and multivariable linear regression analysis is shown. With all factors showing a p-value < 0.05 and adjusted for age and sex, a multivariable linear regression model was built. The variables waist circumference and MetS were excluded from the multivariable analysis to avoid multicollinearity. Confidence interval (CI) and beta (β) show each standardized values. Boldface indicates statistical significance.

A p-value < 0.05 was considered statistically significant.

†Multivariable linear regression analysis (n = 146): age, sex, obesity, AF, CVD, polyneuropathy, DFS, insulin.

Similar results were seen with the VAS. Here, the variables obesity, waist circumference, MetS, AF, CVD, polyneuropathy, DFS, and insulin were associated with a lower HRQL. Age (β: −0.171; 95% CI −0.369, −0.003), obesity (β: −0.247; 95% CI −0.419, -0.077), and AF (β: −0.222; 95% CI −0.383, −0.051) remained the only independent predictors a poor HRQL in the multivariable linear regression analysis (Table 4).

Discussion

In this study, we aimed to analyze the effect size of AF on the HRQL in people with T2DM in primary care in the German DMP using the EQ-5D-3L questionnaire. Overall, the burden of liver-related comorbidities, including SLD and AF, is high in these individuals with a significant impact on the HRQL. The mobility and pain/discomfort dimensions imposed the highest burden. Especially those with AF showed the lowest scores on the VAS and the TTO index value. Although the presence of T2DM-related comorbidities was in part negatively affecting the HRQL, AF, and obesity remained the only independent predictors of an impaired HRQL in this cohort. Thus, obesity and more advanced liver disease may impose a higher impairment of HRQL than other well-known T2DM-related side effects. This has important implications for the consideration of SLD/MASLD and AF in the routine assessment of people with T2DM in disease management programs.

Obesity and AF remained the only independent predictors of HRQL impairment as measured by the VAS and the TTO index value in this cohort. Other studies have also reported the negative impact of higher fibrosis stages, including AF, on the HRQL in patients with MASLD10,25. Moreover, especially people with T2DM and obesity had a greater impairment of the HRQL compared to those without obesity26. In comparison to AF, the detection of SLD was not independently associated with a lower HRQL. Chronic liver diseases, such as MASLD, may lack specific symptoms, especially in earlier stages without MASH and fibrosis. Moreover, obesity may reflect a more obvious sign of a metabolically ill phenotype than MASLD itself, with the result of body dissatisfaction, stigmatization, and discrimination27. Furthermore, obesity can also impose restrictions on routine activities due to physical inability28. In this context, the most burdensome dimensions were mobility, usual activities, and pain/discomfort in people with T2DM and AF/obesity. These findings are in line with previous analyses in chronic conditions other than T2DM29. Physical activity is an important determinant of the HRQL in T2DM and MASLD30,31. This is highly important in the context of lacking pharmacotherapy in MASLD, with lifestyle interventions aiming at weight reduction as the cornerstone of treatment. Obesity and AF could be both self-reinforcing factors from various perspectives with negative effects on the HRQL.

People with T2DM report an overall lower HRQL in comparison to the general population32. The high prevalence of obesity in these individuals may add to the burden of a decreased HRQL, as our study and other studies confirm33. More interestingly, the T2DM-related comorbidities investigated in this study did not remain predictive of a lower HRQL. Previous analyses highlighted the negative effects of comorbidities on the HRQL in people with T2DM14–16. However, none of these studies have specifically addressed liver-related comorbidities despite the high prevalence in these patients2. In this cohort, a higher prevalence of T2DM-related comorbidities was seen in the subgroup with AF. The presence of AF resembles an overall morbid phenotype with a high risk of several other hepatic- and extrahepatic complications, and high mortality6. In a large study of people with T2DM in primary care, obesity did not remain an independent predictor of a lower HRQL which is in contrast to our findings. It was rather the number of symptomatic comorbidities associated with T2DM that showed a high impact on HRQL16. While we did not analyze the number of comorbidities specifically, we argue that the strong effect of AF on the HRQL in our study could be an expression of these multiple in part overlapping factors, especially within the context of T2DM. Implementing a routine assessment of liver fibrosis in people with T2DM may aid in identifying those with an overall higher disease burden and a lower HRQL.

Other studies have shown a higher prevalence and risk of anxiety and depression in people with T2DM and those with MASLD34,35. In this study, anxiety or depression was not specifically assessed. The anxiety/depression dimension of the EQ-5D-3L showed no impairment in the entire cohort and differences between the subgroups, although 31% expressed moderate to extreme problems in this dimension if AF was present. As reported by the VAS, age remained predictive of poor HRQL along with obesity and AF. Other studies have shown that VAS decreases with higher age, which may be related to the addition of more age-related conditions along with common T2DM-related comorbidities36. Furthermore, no difference in the HRQL between males and females was detected, contradictory to other studies highlighting a lower HRQL in females with advanced stages of MASLD13.

Strengths & limitations

A limitation of this study is the highly selected study population and in this regard the lack of a control group without T2DM. However, we here present data from a primary care setting of people with T2DM and with the inclusion of major related comorbidities. In this context, the analyses were adjusted for relevant confounders of an impaired HRQL along with obesity and AF, leading to greater generalizability of these findings in populations with T2DM. Yet, AF is often associated with metabolic risk factors and other comorbidities, and thus multicollinearity in the multivariable analyses cannot entirely be ruled out which may limit the results of this study. Besides MASLD, we have also included cases of SLD with harmful alcohol consumption (alcohol-related liver disease). However, the majority of this cohort presented with MASLD, and the inclusion of harmful alcohol consumption had the purpose of ruling out this confounder on HRQL. The monocentric nature of this study without longitudinal assessment limits the ability to assess causation. Moreover, SLD and AF were defined non-invasively according to VCTE thresholds with the possibility of false negative or false positive findings. Despite inaccuracies of VCTE and CAP for the detection of hepatic steatosis, the threshold used in this study of ≥ 275 dB/m has a sensitivity and positive predictive value of over 90%20.

Conclusions

This study identified obesity and AF as independent predictors of an impaired HRQL in people with T2DM in primary care. These findings highlight the importance of chronic liver disease with AF in the assessment of this high-risk population. Awareness of liver health and specific interventions may improve patient-reported and liver-related outcomes in people with T2DM.

Supplementary Information

Supplementary Figure 1.

Supplementary Tables.

Abbreviations

SLD Steatotic liver disease

MASLD Metabolic dysfunction-associated steatotic liver disease

MASH Metabolic dysfunction-associated steatohepatitis

AF Advanced fibrosis

T2DM Type 2 diabetes mellitus

MetS Metabolic syndrome

NITs Non-invasive tests

VCTE Vibration-controlled transient elastography

HRQL Health-related quality of life

DMP Disease management program

BMI Body mass index

AUDIT Alcohol use disorders identification test

HS Hepatic steatosis

CAP Controlled attenuation parameter

LSM Liver stiffness measurement

TTO Time trade-off

VAS Visual analog scale

CVD Cardiovascular disease

CKD Chronic kidney disease

DFS Diabetic foot syndrome

GGT Gamma-glutamyl transferase

TG Triglycerides

TC Total cholesterol

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-72105-8.

Acknowledgements

MM was supported by the Clinician Scientist Fellowship “Else Kröner Research College: 2018_Kolleg.05”. This study contains parts of the medical thesis of MD (Michelle Doll). We thank all the patients that participated in this study.

Author contributions

Performed research: MM, MD. Contributed to acquisition of data: MM, MD, AA, CL, JMS; Designed the experiments and analyzed the data: MM, JMS; Contributed reagents/materials/analysis tools: PRG, JMS. Wrote the manuscript: MM, JMS. Revised and edited the manuscript: MM, JFS, SAA, AA, CL, PRG, JMS. Statistical analysis: MM, JFS, JMS. All authors approved the final version of the manuscript and the authorship list. Guarantor of the article: JMS.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Data availability

The data presented in this study are available on request from the corresponding author.

Competing interests

JMS reports Consultant: Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Genfit, Gilead Sciences, GSK, Heel GmbH, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Julius Clinical, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shinogi, Siemens Healthcare GmbH, Summit Clinical Research. Research Funding: Gilead Sciences, Boehringer Ingelheim, Nordic Bioscience, Siemens Healthcare GmbH. Speaker Honorarium: MedPublico GmbH, Boehringer Ingelheim. The other authors declare that they have no competing interests.

Ethics approval and consent to participate

Informed consent was obtained from all participants involved in the study.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Younossi Z Golabi P Paik J Henry A van Dongen C Henry L The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A systematic review Hepatology 2023 38112428
Younossi, Z. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A systematic review. Hepatology10.1097/HEP.0000000000000004 (2023).38112428
2. Ajmera V Cepin S Tesfai K Hofflich H Cadman K Lopez S A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes J. Hepatol. 2022 36410554
Ajmera, V. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol.10.1016/j.jhep.2022.11.010 (2022).36410554
3. Quek J Chan KE Wong ZY Tan C Tan B Lim WH Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis Lancet Gastroenterol. Hepatol. 2023 8 20 30 36400097
Quek, J. et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 8, 20–30. 10.1016/S2468-1253(22)00317-X (2023).36400097
4. Michel M Doll M Albert N Morgenstern M Behr A Maxeiner S Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes United Eur. Gastroenterol. J. 2024
Michel, M. et al. Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes. United Eur. Gastroenterol. J.10.1002/ueg2.12511 (2024).
5. Diehl AM Day C Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis N. Engl. J. Med. 2017 377 2063 2072 29166236
Diehl, A. M. & Day, C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N. Engl. J. Med. 377, 2063–2072. 10.1056/NEJMra1503519 (2017).29166236
6. Sanyal AJ van Natta ML Clark J Neuschwander-Tetri BA Diehl A Dasarathy S Prospective study of outcomes in adults with nonalcoholic fatty liver disease N. Engl. J. Med. 2021 385 1559 1569 34670043
Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559–1569. 10.1056/NEJMoa2029349 (2021).34670043
7. Tapper EB Loomba R Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD Nat. Rev. Gastroenterol. Hepatol. 2018 15 274 282 29463906
Tapper, E. B. & Loomba, R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 15, 274–282. 10.1038/nrgastro.2018.10 (2018).29463906
8. Barbosa JV Lai M Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting Hepatol. Commun. 2021 5 158 167 33553966
Barbosa, J. V. & Lai, M. Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting. Hepatol. Commun. 5, 158–167. 10.1002/hep4.1618 (2021).33553966
9. Rabin R de Charro F EQ-5D: A measure of health status from the EuroQol group Ann. Med. 2001 33 337 343 11491192
Rabin, R. & de Charro, F. EQ-5D: A measure of health status from the EuroQol group. Ann. Med. 33, 337–343. 10.3109/07853890109002087 (2001).11491192
10. Younossi ZM Stepanova M Anstee QM Lawitz EJ Wai-Sun Wong V Romero-Gomez M Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis Clin. Gastroenterol. Hepatol. 2019 17 2552 2560.e10 30779990
Younossi, Z. M. et al. Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 17, 2552-2560.e10. 10.1016/j.cgh.2019.02.024 (2019).30779990
11. Konerding U Elkhuizen SG Faubel R Forte P Malmström T Pavi E Janssen MFB The validity of the EQ-5D-3L items: An investigation with type 2 diabetes patients from six European countries Health Qual. Life Outcomes 2014 12 181 25479769
Konerding, U. et al. The validity of the EQ-5D-3L items: An investigation with type 2 diabetes patients from six European countries. Health Qual. Life Outcomes 12, 181. 10.1186/s12955-014-0181-5 (2014).25479769
12. Huber Y Pfirrmann D Gebhardt I Labenz C Gehrke N Straub BK Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program Aliment Pharmacol. Ther. 2019 31583743
Huber, Y. et al. Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Aliment Pharmacol. Ther.10.1111/apt.15427 (2019).31583743
13. Huber Y Boyle M Hallsworth K Tiniakos D Straub BK Labenz C Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation Clin. Gastroenterol. Hepatol. 2019 17 2085 2092.e1 30580090
Huber, Y. et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin. Gastroenterol. Hepatol. 17, 2085-2092.e1. 10.1016/j.cgh.2018.12.016 (2019).30580090
14. Mehta Z Cull C Stratton I Yudkin J Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. prospective diabetes study group Diabetes Care 1999 22 1125 1136 10388978
Mehta, Z., Cull, C., Stratton, I. & Yudkin, J. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. prospective diabetes study group. Diabetes Care 22, 1125–1136. 10.2337/diacare.22.7.1125 (1999).10388978
15. Wexler DJ Grant RW Wittenberg E Bosch JL Cagliero E Delahanty L Correlates of health-related quality of life in type 2 diabetes Diabetologia 2006 49 1489 1497 16752167
Wexler, D. J. et al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia 49, 1489–1497. 10.1007/s00125-006-0249-9 (2006).16752167
16. Wermeling PR Gorter KJ van Stel HF Rutten GEHM Both cardiovascular and non-cardiovascular comorbidity are related to health status in well-controlled type 2 diabetes patients: A cross-sectional analysis Cardiovasc. Diabetol. 2012 11 121 23039172
Wermeling, P. R., Gorter, K. J., van Stel, H. F. & Rutten, G. E. H. M. Both cardiovascular and non-cardiovascular comorbidity are related to health status in well-controlled type 2 diabetes patients: A cross-sectional analysis. Cardiovasc. Diabetol. 11, 121. 10.1186/1475-2840-11-121 (2012).23039172
17. Gemeinsamer Bundesausschuss. DMP-Anforderungen-Richtlinie: Richtlinie zur Zusammenführung der Anforderungen an strukturierte Behandlungsprogramme nach § 137f Abs. 2 SGB V – DMP-A-RL. (2022). https://www.g-ba.de/downloads/62-492-3454/DMP-A-RL_2023-11-16_iK-2024-07-01.pdf. Accessed 10 July 2024.
18. International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html. Accessed 10 July 2024.
19. Saunders JB Aasland OG Babor TF de Fuente JR Grant M Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II Addiction 1993 88 791 804 8329970
Saunders, J. B., Aasland, O. G., Babor, T. F., de Fuente, J. R. & Grant, M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 88, 791–804. 10.1111/j.1360-0443.1993.tb02093.x (1993).8329970
20. Berzigotti A Tsochatzis E Boursier J Castera L Cazzagon N Friedrich-Rust M EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update J. Hepat. 2021 75 659 689
Berzigotti, A. et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J. Hepat. 75, 659–689. 10.1016/j.jhep.2021.05.025 (2021).
21. Rinella ME Lazarus JV Ratziu V Francque SM Sanyal AJ Kanwal F A multi-society Delphi consensus statement on new fatty liver disease nomenclature J. Hepatol. 2023 38906627
Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol.10.1016/j.jhep.2023.06.003 (2023).38906627
22. Hui Y Li N Yu Z Li C Wang X Li Y Health-related quality of life and its contributors according to a preference-based generic instrument in cirrhosis Hepatol. Commun. 2021 34558226
Hui, Y. et al. Health-related quality of life and its contributors according to a preference-based generic instrument in cirrhosis. Hepatol. Commun.10.1002/hep4.1827 (2021).34558226
23. Greiner W Claes C Busschbach JJV von Schulenburg J-MG Validating the EQ-5D with time trade off for the German population Eur. J. Health Econ. 2005 6 124 130 19787848
Greiner, W., Claes, C., Busschbach, J. J. V. & von Schulenburg, J.-M.G. Validating the EQ-5D with time trade off for the German population. Eur. J. Health Econ. 6, 124–130. 10.1007/s10198-004-0264-z (2005).19787848
24. Cohen J Statistical Power Analysis for the Behavioral Sciences 2013 Routledge
Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Routledge, 2013).
25. Yilmaz Y Toraman AE Alp C Doğan Z Keklikkiran C Stepanova M Younossi Z Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: A registry-based study Aliment Pharmacol. Ther. 2022 36369643
Yilmaz, Y. et al. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: A registry-based study. Aliment Pharmacol. Ther.10.1111/apt.17301 (2022).36369643
26. Gough S Kragh N Ploug UJ Hamme M Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England DMSO 2009 2 179 184
Gough, S., Kragh, N., Ploug, U. J. & Hamme, M. Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England. DMSO 2, 179–184. 10.2147/DMSO.S7088 (2009).
27. Phelan SM Burgess DJ Yeazel MW Hellerstedt WL Griffin JM van Ryn M Impact of weight bias and stigma on quality of care and outcomes for patients with obesity Obes. Rev. 2015 16 319 326 25752756
Phelan, S. M. et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes. Rev. 16, 319–326. 10.1111/obr.12266 (2015).25752756
28. Younossi ZM Stepanova M Henry L Racila A Lam B Pham HT Hunt S A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD Liver Int. 2017 37 1209 1218 28211165
Younossi, Z. M. et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int. 37, 1209–1218. 10.1111/liv.13391 (2017).28211165
29. Michel M Labenz C Anders M Wahl A Girolstein L Kaps L Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV Hepatol. Commun. 2022 35411570
Michel, M. et al. Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. Hepatol. Commun.10.1002/hep4.1958 (2022).35411570
30. Tapper EB Lai M Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study Hepatology 2016 63 1184 1189 26698379
Tapper, E. B. & Lai, M. Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study. Hepatology 63, 1184–1189. 10.1002/hep.28416 (2016).26698379
31. Lean ME Leslie WS Barnes AC Brosnahan N Thom G McCombie L Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial Lancet 2018 391 541 551 29221645
Lean, M. E. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. Lancet 391, 541–551. 10.1016/S0140-6736(17)33102-1 (2018).29221645
32. Rubin RR Peyrot M Quality of life and diabetes Diabetes Metab. Res. Rev. 1999 15 205 218 10441043
Rubin, R. R. & Peyrot, M. Quality of life and diabetes. Diabetes Metab. Res. Rev. 15, 205–218 (1999).10441043
33. Funuyet-Salas J Pérez-San-Gregorio MÁ Martín-Rodríguez A Romero-Gómez M Quality of life and coping in nonalcoholic fatty liver disease: Influence of diabetes and obesity Int. J. Environ. Res. Public Health 2021 18 3503 33800585
Funuyet-Salas, J., Pérez-San-Gregorio, M. Á., Martín-Rodríguez, A. & Romero-Gómez, M. Quality of life and coping in nonalcoholic fatty liver disease: Influence of diabetes and obesity. Int. J. Environ. Res. Public Health 18, 3503. 10.3390/ijerph18073503 (2021).33800585
34. Moulton CD Pickup JC Ismail K The link between depression and diabetes: The search for shared mechanisms Lancet Diabetes Endocrinol. 2015 3 461 471 25995124
Moulton, C. D., Pickup, J. C. & Ismail, K. The link between depression and diabetes: The search for shared mechanisms. Lancet Diabetes Endocrinol. 3, 461–471. 10.1016/S2213-8587(15)00134-5 (2015).25995124
35. Labenz C Huber Y Michel M Nagel M Galle PR Kostev K Schattenberg JM Nonalcoholic fatty liver disease increases the risk of anxiety and depression Hepatol. Commun. 2020 32923833
Labenz, C. et al. Nonalcoholic fatty liver disease increases the risk of anxiety and depression. Hepatol. Commun.10.1002/hep4.1541 (2020).32923833
36. Huber MB Felix J Vogelmann M Leidl R Health-related quality of life of the general German population in 2015: Results from the EQ-5D-5L Int. J. Environ. Res. Public Health 2017 14 426 28420153
Huber, M. B., Felix, J., Vogelmann, M. & Leidl, R. Health-related quality of life of the general German population in 2015: Results from the EQ-5D-5L. Int. J. Environ. Res. Public Health 14, 426. 10.3390/ijerph14040426 (2017).28420153
